SCHEMBL1779183

SCHEMBL1779183

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)cc2N)c2cc(C(=O)NC(C)(C)c3ccccc3F)sc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 4/20 0.42
INSR P06213 3/20 0.42
IGF1R P08069 1/20 0.42
BTK Q06187 3/20 0.40
AURKA O14965 4/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KIT P10721 1/20 0.36
FLT3 P36888 1/20 0.36
PDE7A Q13946 3/20 0.35
MAPK14 Q16539 1/20 0.34
WDR5 P61964 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1777102 0.91 AURKA (0.48) ALKINSRIGF1RBTKAURKA
SCHEMBL1780225 0.90 SIRT6 (0.39) ALKINSRBTKAURKAABL1
SCHEMBL1779011 0.88 IGF1R (0.43) ALKINSRIGF1RBTKAURKA
SCHEMBL1780516 0.87 KDM4E (0.38) KDM4EMEN1ALDH1A1GAAMAPK1
SCHEMBL1778613 0.87 BTK (0.40) ALKINSRIGF1RBTKAURKA
SCHEMBL1779824 0.87 RAF1 (0.38) ALKINSRIGF1RBTKAURKA
SCHEMBL1777980 0.87 AURKA (0.40) ALKINSRIGF1RBTKAURKA
SCHEMBL1778668 0.86 PDE7A (0.41) ALKINSRIGF1RBTKAURKA
SCHEMBL1777894 0.85 ALK (0.43) ALKINSRIGF1RBTKAURKA
SCHEMBL1779035 0.81 ABL1 (0.47) BTKAURKAABL1BCRPDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 ALK 423/4885INSR 1010/4885IGF1R 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.